Torasemide Tablets 托拉塞米片
Torasemide Injection 托拉塞米注射液
Torasemide Capsules 托拉塞米胶囊
Torasemide Tables 托拉塞米片
Torasemide for Injection 注射用托拉塞米
Torasemide anhydrous 托拉塞米
Torasemide Dispersible Tables 托拉塞米分散片
Torasemide for system suitability 托拉塞米
Torasemide impurity 托拉塞米杂质
Objective：To establish a HPLC method to determine the content of the residual starting materials, 4-hydroxypyridine and m-tuloidine, in torasemide drug substance.
目的：建立高效液相色谱法控制原料药托拉塞米中起始原料4-羟基吡啶与间甲苯胺的残留量的分析方法。
参考来源 - 托拉塞米产品中起始原料残留量分析方法的研究—《中国医药导报》—2008年第26期—龙源期刊网·2,447,543篇论文数据，部分数据来源于NoteExpress
The research of physicochemical property of torasemide provide the basements for the later researches;
托拉塞米的理化性质研究为缓释片的研究工作提供了必要的基础；
The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and pharmaco economics of torasemide are reviewed.
综述托拉·塞米的药理作用、药动学、临床应用、药物不良反应和药物经济学。
There were no remarkable effects in liver function, kidney function, blood and urine routine analysis, electrocardiography after taken torasemide for 8 weeks.
服用后8周实验药对肝肾功能、血尿常规及心电图均无明显影响。
应用推荐